+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neuromodulation Market Research Report by Technology (Deep Brain Stimulation, Gastric Stimulation, and Sacral Nerve Stimulation), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4968620
  • Report
  • April 2022
  • Region: Global
  • 182 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022
The Global Neuromodulation Market size was estimated at USD 7,079.08 million in 2021, USD 7,801.89 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.38% to reach USD 12,808.43 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Neuromodulation to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the market was studied across Deep Brain Stimulation, Gastric Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, and Vagus Nerve Stimulation.
  • Based on Application, the market was studied across Chronic Pain, Dystonia, Essential Tremor, Gastroparesis, Obsessive Compulsive Disorder, Parkinson’s Disease, Refractory Epilepsy, Treatment Resistant Depression, and Urinary Fecal Incontinence.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neuromodulation market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuromodulation Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuromodulation Market, including Advanced Bionics, Boston Scientific Corporation, Cochlear Ltd., Cyberonics, Greatbatch, Medtronic Plc, Neuronetics, Inc., Nevro Corporation, Sonova Group, and St. Jude Medical.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Neuromodulation Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuromodulation Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuromodulation Market?
4. What is the competitive strategic window for opportunities in the Global Neuromodulation Market?
5. What are the technology trends and regulatory frameworks in the Global Neuromodulation Market?
6. What is the market share of the leading vendors in the Global Neuromodulation Market?
7. What modes and strategic moves are considered suitable for entering the Global Neuromodulation Market?
Frequently Asked Questions about the Global Neuromodulation Market

What is the estimated value of the Global Neuromodulation Market?

The Global Neuromodulation Market was estimated to be valued at $7079.1 Million in 2021.

What is the growth rate of the Global Neuromodulation Market?

The growth rate of the Global Neuromodulation Market is 10.3%, with an estimated value of $12808.4 Million by 2027.

What is the forecasted size of the Global Neuromodulation Market?

The Global Neuromodulation Market is estimated to be worth $12808.4 Million by 2027.

Who are the key companies in the Global Neuromodulation Market?

Key companies in the Global Neuromodulation Market include Advanced Bionics, Boston Scientific Corporation, Cochlear Ltd., Cyberonics, Greatbatch, Medtronic Plc, Neuronetics, Inc., Nevro Corporation and St. Jude Medical.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the aging population and rising prevalence of neurological disorders
5.1.1.2. Broadened research for expanding the applications of neuromodulation, new indications and target applications
5.1.1.3. Rising vulnerability for neurological disorders
5.1.2. Restraints
5.1.2.1. High cost of neuromodulation treatment and equipment, coupled with the dearth of a trained medical professionals
5.1.2.2. Inconsistent reimbursement policies
5.1.3. Opportunities
5.1.3.1. Presence of major market players and growing R&D activity in pharmaceutical and biopharmaceutical industry
5.1.3.2. Rising investments for the adoption of advanced technologies coupled with expansion in emerging economies
5.1.4. Challenges
5.1.4.1. Ethical problems and acceptance issues of neurological disorders
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Neuromodulation Market, by Technology
6.1. Introduction
6.2. Deep Brain Stimulation
6.3. Gastric Stimulation
6.4. Sacral Nerve Stimulation
6.5. Spinal Cord Stimulation
6.6. Vagus Nerve Stimulation
7. Neuromodulation Market, by Application
7.1. Introduction
7.2. Chronic Pain
7.3. Dystonia
7.4. Essential Tremor
7.5. Gastroparesis
7.6. Obsessive Compulsive Disorder
7.7. Parkinson’s Disease
7.8. Refractory Epilepsy
7.9. Treatment Resistant Depression
7.10. Urinary Fecal Incontinence
8. Americas Neuromodulation Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Neuromodulation Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Neuromodulation Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Advanced Bionics
12.2. Boston Scientific Corporation
12.3. Cochlear Ltd.
12.4. Cyberonics
12.5. Greatbatch
12.6. Medtronic Plc
12.7. Neuronetics, Inc.
12.8. Nevro Corporation
12.9. Sonova Group
12.10. St. Jude Medical
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL NEUROMODULATION MARKET: DYNAMICS
FIGURE 2. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (%)
FIGURE 3. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2027
FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2027
FIGURE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, 2019-2027 (USD MILLION)
FIGURE 27. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, 2019-2027 (USD MILLION)
FIGURE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, 2019-2027 (USD MILLION)
FIGURE 31. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 32. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, 2019-2027 (USD MILLION)
FIGURE 33. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 34. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, 2019-2027 (USD MILLION)
FIGURE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 36. AMERICAS NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. ARGENTINA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. BRAZIL NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. CANADA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. MEXICO NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. UNITED STATES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. AUSTRALIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. CHINA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. INDIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. INDONESIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. JAPAN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. MALAYSIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. PHILIPPINES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. SINGAPORE NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. SOUTH KOREA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. TAIWAN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. THAILAND NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. FRANCE NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. GERMANY NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. ITALY NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. NETHERLANDS NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. QATAR NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. RUSSIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. SAUDI ARABIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. SOUTH AFRICA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. SPAIN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. UNITED KINGDOM NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. GLOBAL NEUROMODULATION MARKET: FPNV POSITIONING MATRIX
FIGURE 67. GLOBAL NEUROMODULATION MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 68. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEUROMODULATION MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL NEUROMODULATION MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 20. AMERICAS NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 25. AMERICAS NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 27. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2019-2027 (USD MILLION)
TABLE 41. AMERICAS NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. UNITED STATES NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 43. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 46. AMERICAS NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. UNITED STATES NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 48. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2019-2027 (USD MILLION)
TABLE 51. AMERICAS NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 52. UNITED STATES NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY STATE, 2019-2027 (USD MILLION)
TABLE 53. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2019-2027 (USD MILLION)
TABLE 56. AMERICAS NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 57. UNITED STATES NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY STATE, 2019-2027 (USD MILLION)
TABLE 58. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY PARKINSON’S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 60. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2019-2027 (USD MILLION)
TABLE 61. AMERICAS NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 62. UNITED STATES NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY STATE, 2019-2027 (USD MILLION)
TABLE 63. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 65. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2019-2027 (USD MILLION)
TABLE 66. AMERICAS NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 67. UNITED STATES NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY STATE, 2019-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 70. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2019-2027 (USD MILLION)
TABLE 71. AMERICAS NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 72. UNITED STATES NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY STATE, 2019-2027 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 75. AMERICAS NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 76. ARGENTINA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. BRAZIL NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. CANADA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 79. MEXICO NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. UNITED STATES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 82. AUSTRALIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. CHINA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. INDIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 85. INDONESIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. JAPAN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 87. MALAYSIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 88. PHILIPPINES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 89. SINGAPORE NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. SOUTH KOREA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 91. TAIWAN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 92. THAILAND NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 94. FRANCE NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 95. GERMANY NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 96. ITALY NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 97. NETHERLANDS NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 98. QATAR NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. RUSSIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 100. SAUDI ARABIA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 101. SOUTH AFRICA NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 102. SPAIN NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 103. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 104. UNITED KINGDOM NEUROMODULATION MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 105. GLOBAL NEUROMODULATION MARKET: SCORES
TABLE 106. GLOBAL NEUROMODULATION MARKET: BUSINESS STRATEGY
TABLE 107. GLOBAL NEUROMODULATION MARKET: PRODUCT SATISFACTION
TABLE 108. GLOBAL NEUROMODULATION MARKET: RANKING
TABLE 109. GLOBAL NEUROMODULATION MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 110. GLOBAL NEUROMODULATION MARKET: MERGER & ACQUISITION
TABLE 111. GLOBAL NEUROMODULATION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 112. GLOBAL NEUROMODULATION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 113. GLOBAL NEUROMODULATION MARKET: INVESTMENT & FUNDING
TABLE 114. GLOBAL NEUROMODULATION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 115. GLOBAL NEUROMODULATION MARKET: LICENSE & PRICING

Companies Mentioned

  • Advanced Bionics
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • Cyberonics
  • Greatbatch
  • Medtronic Plc
  • Neuronetics, Inc.
  • Nevro Corporation
  • Sonova Group
  • St. Jude Medical

Methodology

Loading
LOADING...